Frontlight ResearchEarly access
CompletedNo phase
Liver Biomarkers in Anorexia Nervosa
Key facts
- Who runs it
- Nantes University Hospital
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 43 people enrolled
- Started
- 23 Jun 2023
- Ended
- 27 Jun 2025
- Type of study
- Observational
- Treatments tested
- Fibroscan
- Record updated
- 17 April 2026
Who can take part
- Age
- 15 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patient over 15 years old
- Diagnosis of Restricted Eating Disorders including Anorexia Nervosa according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
- Admission to the endocrinology, diabetology and nutrition department of the Nantes University Hospital
Who cannot take part
- Treatment with a drug known to induce fatty liver disease (amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retrovirals) unless the dose has been stable for ≥ 3 months
- Chronic active viral hepatitis
- Other genetic, autoimmune, toxic or drug-induced hepatitis
- Hemochromatosis
- Excessive alcohol consumption (≥ 30 grams per day in men, ≥ 20 grams per day in women)
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main goal of the Liver Biomarkers in Anorexia Nervosa (LIBAN) study is to determine the prevalence of liver fibrosis in patient with Anorexia Nervosa.
The group in the trial
- Non applicable (NA)
Patients with Anorexia Nervosa hospitalized for malnutrition
Treatment: Fibroscan
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Assessment of Liver Damage Using the Fibroscan in Patients With Anorexia Nervosa
- Record updated
- 17 April 2026